Clinical Trial

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Study acronym: XMaS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A pilot study to assess the safety and tolerability of an orally administered natural product derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestinal microorganisms in that signature within adults with Crohn's Disease.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-10-15; most recent amendment 2025-12-01.
Status change: Recruiting → Active, Not Recruiting 2024-08-02
Trial Details
NCT Number NCT04590508
Lead Sponsor National University of Natural Medicine
Collaborators: Oregon State University, Pacific Northwest National Laboratory
Conditions Crohn Disease
Enrollment 20 participants
Start Date 2020-10-01
Primary Completion 2024-08-22 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-18